

1           **Title: Humoral and cellular immune correlates of protection against**  
2                                   **COVID-19 in kidney transplant recipients**

3  
4   **Authors:**

5   D. Kemlin<sup>1,2\*</sup>, N. Gemander<sup>1</sup>, S. Depickère<sup>3</sup>, V. Orlislagers<sup>1</sup>, D. Georges<sup>1,7</sup>, A. Waegemans<sup>1</sup>, P.  
6   Pannus<sup>3</sup>, A. Lemy<sup>4</sup>, M. E. Goossens<sup>3</sup>, I. Desombere<sup>3</sup>, J. Michiels<sup>5</sup>, M. Vandevenne<sup>7</sup>, L.  
7   Heyndrickx<sup>5</sup>, K.K. Ariën<sup>5,6</sup>, A. Matagne<sup>7</sup>, M.E. Ackerman<sup>8</sup>, A. Le Moine<sup>2</sup>, A. Marchant<sup>1,\*</sup>.

8  
9   **Affiliations :**

10   <sup>1</sup> Institute for Medical Immunology and ULB Centre for Research in Immunology (U-CRI),  
11   Université Libre de Bruxelles (ULB), Gosselies, Belgium

12   <sup>2</sup> Department of Nephrology, Dialysis and Transplantation, Erasme Hospital, Université Libre  
13   de Bruxelles (ULB), Brussels, Belgium

14   <sup>3</sup> Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium

15   <sup>4</sup> Department of Nephrology, Marie Curie Hospital, Charleroi, Belgium

16   <sup>5</sup> Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp,  
17   Belgium

18   <sup>6</sup> Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium

19   <sup>7</sup> Laboratory of Enzymology and Protein Folding, Centre for Protein Engineering, InBioS,  
20   University of Liège, Liège, Belgium

21   <sup>8</sup> Thayer School of Engineering, Dartmouth College, Hanover, NH, USA

22   \* Corresponding authors. Email: [delphine.kemlin@erasme.ulb.ac.be](mailto:delphine.kemlin@erasme.ulb.ac.be); [arnaud.marchant@ulb.be](mailto:arnaud.marchant@ulb.be)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 1 **One Sentence Summary:** Antibody and T cell responses to booster SARS-CoV-2 vaccination
- 2 predict the risk of symptomatic breakthrough infection in kidney transplant recipients
- 3

1 **Abstract:**

2 As solid organ recipients are at high risk of severe COVID-19 and respond poorly to  
3 primary SARS-CoV-2 mRNA vaccination, they have been prioritized for booster vaccination.  
4 However, an immunological correlate of protection has not been identified in this vulnerable  
5 population. We conducted a prospective monocentric cohort study of 65 kidney transplant  
6 recipients who received three doses of SARS-CoV-2 BNT162b2 mRNA vaccination.  
7 Associations between symptomatic breakthrough infection (BTI) and vaccine responses,  
8 patient demographic and clinical characteristics were explored. Symptomatic COVID-19 was  
9 diagnosed in 32% of kidney transplant recipients during a period of six months after the  
10 administration of the third vaccine dose. During this period, SARS-CoV-2 delta and omicron  
11 were the dominant variants in the general population. Univariate analyzes identified avidity of  
12 SARS-CoV-2 receptor binding domain (RBD) binding IgG, neutralizing antibodies and SARS-  
13 CoV-2 S2 domain-specific IFN- $\gamma$  responses as correlates of protection against BTI. Some  
14 demographic and clinical parameters correlated with vaccine responses, but none correlated  
15 with the risk of BTI. In multivariate analysis, the risk of BTI was best predicted by neutralizing  
16 antibody and S2-specific IFN- $\gamma$  responses, adjusting for age, graft function and mycophenolate  
17 mofetil use. In conclusion, both antibody and T cell responses predict the risk of BTI in kidney  
18 transplant recipients who received three doses of SARS-CoV-2 mRNA vaccine. T cell  
19 responses may help compensate for the suboptimal antibody response to vaccination in this  
20 vulnerable population.

1 **Main text:**

2 **INTRODUCTION**

3 Solid organ transplant (SOT) recipients are at high risk of severe COVID-19 and death  
4 (*1–4*). This high risk has been attributed to immunosuppressive therapies and to common co-  
5 morbidities, including cardiovascular disease, diabetes, and obesity, that have also been  
6 associated with severe COVID-19 and death in the general population (*5, 6*). While they had  
7 not been included in COVID-19 vaccine trials, SOT recipients were offered COVID-19  
8 vaccination early in vaccination campaigns. Unfortunately, their responses to COVID-19  
9 vaccines were weaker than those of healthy adults: neutralizing antibodies were not detectable  
10 in most patients, even after two doses of mRNA vaccine (*7*). These low vaccine responses were  
11 associated with a high incidence of breakthrough infections (BTI), including severe cases (*8–*  
12 *12*). SOT recipients were therefore prioritized for a booster with a third dose of COVID-19  
13 vaccine. Higher levels of SARS-CoV-2 neutralizing antibodies were induced by booster as  
14 compared to primary vaccination in these patients, in line with what is observed in the general  
15 population (*13–15*). Yet, the level of immunity against BTI achieved by booster vaccination of  
16 SOT recipients, especially in the context of emerging SARS-CoV-2 variants, remains poorly  
17 defined (*16*).

18 Serum levels of SARS-CoV-2 neutralizing antibodies are correlated with protection  
19 against COVID-19 in the general population (*17–20*). In addition, booster mRNA vaccination  
20 is associated with improved vaccine effectiveness in healthy adults (*21*). An immune correlate  
21 of protection against COVID-19 in SOT patients has not been identified. Despite their lower  
22 levels in SOT recipients, neutralizing antibodies are likely to play a key role given their  
23 importance in other populations. On the other hand, other immune effectors, in particular T  
24 lymphocytes, could contribute to protection in patients with limited vaccine-induced humoral  
25 immunity. Notably, no clinical study has yet identified a correlation between T cell responses

1 to vaccination and protection against COVID-19 in the general population, possibly because of  
2 a dominant role for neutralizing antibodies when induced at high levels (22).

3 Sociodemographic and clinical factors could also contribute to the risk of BTI in SOT  
4 patients. Previous studies identified age, female gender and co-morbidities, such as metabolic  
5 syndrome and kidney disease, as risk factors for SARS-CoV-2 BTI (23, 24). It is unclear  
6 whether these factors increase the risk of BTI directly, or by reducing the immune response to  
7 COVID-19 vaccination. Identifying risk factors for BTI in SOT recipients and their potential  
8 impact on COVID-19 vaccine immunogenicity is required to identify high risk patients and to  
9 guide COVID-19 booster immunization strategies.

10 This prospective cohort study was undertaken to identify risk factors of BTI in kidney  
11 transplant recipients who had received three doses of BNT162b2 COVID-19 mRNA vaccine.  
12 Associations with vaccine-induced immune responses, sociodemographic and clinical factors  
13 were explored.

## 1 **RESULTS**

### 2 *Study population*

3 Sixty-six kidney transplant recipients were screened for the study. One patient was excluded  
4 because of a positive PCR test on the day of the first COVID-19 vaccination. Characteristics of  
5 the 65 patients included in the study are shown in table S1. Mean age was 58.2 years. Mean  
6 duration of transplantation was 7.4 years. Immunosuppressive treatment included steroids  
7 (78%), mycophenolate mofetil (52%), azathioprine (25%), tacrolimus (68%), cyclosporine  
8 (14%) and everolimus (23%). During follow-up, one patient required chronic dialysis, one  
9 patient withdrew consent, one patient was lost to follow-up between the second and the third  
10 vaccination, and two patients declined the third dose of vaccine (Fig. 1). No patients died during  
11 the study period.

12

### 13 *Incidence of SARS-CoV-2 BTI*

14 Six cases of symptomatic SARS-CoV-2 BTI were diagnosed between the second and the third  
15 COVID-19 vaccination. Thus, 54 patients were followed-up and received the third dose of  
16 vaccine, on average 161 days after having received the first vaccine dose (Fig. 1). One case of  
17 symptomatic BTI was diagnosed within 28 days of the third dose of vaccine. At D3D28, 53  
18 patients remained free of symptomatic BTI. Seventeen cases were diagnosed between 28 days  
19 after the third vaccination and the fourth vaccination, when the study follow-up ended (Fig. 1).  
20 Symptoms related to BTI are shown in table S2. One patient experienced moderate COVID-19  
21 requiring oxygen supply, and the other 16 patients had mild COVID-19. Curative monoclonal  
22 antibodies were administered to 14 patients (83%). At the end of the study period, 36 patients  
23 remained free of symptomatic BTI.

24

1 Figure 2 depicts the cumulative number of symptomatic BTI in the study population over time  
2 and in relation to the incidence of SARS-CoV-2 infection with individual variants of concern  
3 in the Belgian population. During the first period (before D3D28), the incidence rate of SARS-  
4 CoV-2 BTI in the study population was 0.63 (0.25; 1.30) cases per 1000 person-days. During  
5 this period, the daily incidence of COVID-19 was estimated at less than 1 case per 1000  
6 inhabitants in Belgium, and the alpha and delta VOC were dominant. During the second period  
7 (after D3D28), the incidence rate of BTI in the study population was about 4-fold higher: 2.74  
8 (1.60; 4.38) cases per 1000 persons-days (comparison of incidence rates between the two  
9 periods:  $p < 0.001$ ). During this second period, the estimated incidence of COVID-19 also  
10 increased in the Belgian population and the delta and BA.1 omicron VOC were dominant (Fig.  
11 2).

12

### 13 *Immune response to COVID-19 vaccination*

14 Administration of a third dose of COVID-19 vaccine significantly increased the levels and  
15 quality of SARS-CoV-2 spike-specific antibodies (Fig. 3 and table S3). Geometric mean serum  
16 concentration of RBD binding IgG increased from 8 IU/mL after two doses of vaccine to 35  
17 IU/mL after three vaccine doses. The proportion of patients with detectable RBD binding IgG  
18 was 51% after three vaccinations (27/53). Avidity of RBD binding IgG also increased in  
19 patients with detectable RBD IgG with a five-fold slower dissociation rate between the second  
20 and third dose of vaccine (from geometric mean of  $k_{\text{off}} : 0.0016 \text{ s}^{-1}$  after the second dose to  
21 geometric mean of  $k_{\text{off}} : 0.0003 \text{ s}^{-1}$  after the third dose of vaccine). Neutralizing antibody levels  
22 increased similarly, with only 2% of patients having detectable SARS-CoV-2 neutralizing  
23 antibodies after two doses and 45% of patients after three vaccine doses. In contrast, cellular  
24 immune responses to SARS-CoV-2 were similar after the second and third doses of vaccine  
25 (Fig. 3 and table S3).

1

2 *Risk factors of SARS-CoV-2 BTI following booster COVID-19 vaccination*

3 Potential risk factors for SARS-CoV-2 BTI after the third dose of COVID-19 vaccine were first  
4 explored by univariate analysis using logistic regression (Fig. 4 and table S4). An increased risk  
5 of BTI in kidney transplant recipients was associated with low RBD IgG avidity (odds ratio  
6 (95% CI): 0.07 (0.003; 0.61),  $p=0.04$ ), low titer of neutralizing antibodies (0.15 (0.02; 0.64),  
7  $p=0.027$ ), and low frequency of S2-specific, and not S1-specific, IFN $\gamma$ -producing cells (0.30  
8 (0.11; 0.69),  $p=0.009$ ). No significant association was detected between the risk of BTI  
9 following booster COVID-19 vaccination and the demographic or clinical variables that were  
10 analyzed (Fig. 4 and table S4).

11 The absence of significant association between demographic and clinical variables and the risk  
12 of BTI led us to explore their potential association with the immune response to COVID-19  
13 vaccination. As shown in table S5, older age was associated with lower humoral immune  
14 responses to booster vaccination. Lower kidney graft function and mycophenolate mofetil use  
15 were associated with lower humoral and cellular immune responses to booster vaccination,  
16 whereas the use of azathioprine was associated with higher vaccine responses. Together, these  
17 results indicate that demographic and clinical variables are associated with differences in  
18 immune responses to booster COVID-19 vaccination in kidney transplant recipients even if  
19 they are not significantly associated with the risk of BTI in this population.

20

21 *Multi-parametric analysis of immune response to booster COVID vaccination and the risk of*  
22 *BTI*

23 Multi-parametric serology analyzes were performed to further explore the association between  
24 immune response to booster vaccination and the risk of BTI in kidney transplant recipients.



1 In multi-parametric analysis, patients who developed SARS-CoV-2 BTI after booster  
2 vaccination had significantly lower RBD binding IgG titer and lower levels of neutralizing  
3 antibodies as compared to patients who remained free of symptomatic BTI (Fig. 5A). A similar  
4 same trend was observed with RBD IgG avidity. Patients with BTI also had lower levels of S1-  
5 specific, but not S2-specific, binding IgG (Fig. 5B). In parallel, patients with BTI had lower  
6 levels of S1-specific, but not S2-specific, IgG activating cellular phagocytosis (antibody-  
7 dependent cellular phagocytosis, ADCP). After booster vaccination, only few patients had  
8 detectable neutralizing antibodies against delta (n=4), omicron BA.1 (n=1) and omicron BA.2  
9 (n=4) (table S6). None of them developed symptomatic BTI. Analysis of cellular immune  
10 responses confirmed the results of the univariate analysis (Fig. 4): patients with BTI had  
11 significantly lower frequencies of S2-specific, and not S1-specific, IFN- $\gamma$  producing cells, as  
12 compared to patients with no BTI (Fig. 5C). Humoral immune response parameters (RBD IgG,  
13 RBD IgG avidity, Wuhan NT<sub>50</sub>, S1 IgG, S2 IgG, S1 IgG ADCP and S2 IgG ADCP) were highly  
14 correlated (Fig. 5D). In contrast, significant but lower correlations were observed between  
15 humoral and cellular immune response (S1 IFN- $\gamma$  and S2 IFN- $\gamma$ ) parameters.

16

### 17 *Multivariate analysis of risk factors of BTI*

18 Multivariate analysis was performed to identify the immunological factors that best predicted  
19 the risk of BTI following booster vaccination. Based on the associations observed between  
20 clinical variables and COVID-19 vaccine responses (table S5), this analysis was adjusted for  
21 age, kidney graft function (eGFR) and mycophenolate use. Only variables with a variance  
22 inflation factor (VIF) <10 (RBD binding IgG, Wuhan NT<sub>50</sub>, S1 IgG, S2 IFN- $\gamma$ ) were included  
23 in the analysis. Wuhan neutralizing antibody titer and S2 IFN- $\gamma$  responses were the best  
24 predictors of BTI following booster vaccination, with odds ratios of 0.036 ((<0.001; 0.501),  
25 p=0.028) and 0.145 ((0.016; 0.671), p=0.037), respectively. Based on this analysis, we

- 1 estimated that patients with a 10-fold increase in Wuhan NT<sub>50</sub> had on average a 28-fold lower
- 2 risk of BTI and patients with a 10-fold increase in S2 IFN- $\gamma$  responses had on average a 7-fold
- 3 lower risk of BTI.

## 1 **DISCUSSION**

2 In this prospective cohort study, we observed that both humoral and cellular immune responses  
3 to booster COVID-19 vaccination predict the risk of symptomatic BTI in kidney transplant  
4 recipients. Although age, kidney graft function and the use of mycophenolate were associated  
5 with altered vaccine responses, no significant association was observed between these  
6 parameters, or other demographic and clinical parameters, and the occurrence of BTI. These  
7 data emphasize the importance of inducing adequate immunity through vaccination to protect  
8 this vulnerable population from COVID-19.

9 Our analysis was focused on kidney transplant recipients who had not been diagnosed with  
10 COVID-19 either before vaccination or before the response to booster vaccination was  
11 measured. Patients had low humoral immune responses after two doses of mRNA vaccine,  
12 confirming previous studies in SOT recipients (13–15). Humoral immunity was significantly  
13 enhanced by booster vaccination, as observed in the general population (21). In contrast,  
14 cellular immune responses were similar following two doses of vaccination and after booster  
15 vaccination. Enhanced cellular immune responses following booster vaccination was observed  
16 in the general population, suggesting that boosting of cellular immunity may be more difficult  
17 to achieve in SOT recipients as compared to healthy adults (25). Despite enhanced immunity  
18 following booster vaccination, patients remained at high risk of SARS-CoV-2 BTI. Thirty two  
19 percent of our study population developed symptomatic BTI in the first 6 months following  
20 booster vaccination. This incidence was significantly higher than the one observed before  
21 booster vaccination, most likely because of the higher virus circulation of delta and omicron  
22 VOC during this period. This observation further emphasizes the importance of booster  
23 vaccination to prevent COVID-19 in SOT recipients (8, 9). Most patients received therapeutic  
24 monoclonal antibodies to prevent severe COVID-19 and only one patient required oxygen  
25 supplementation.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

To our knowledge, this is the first report on correlate of protection against COVID-19 in SOT recipients. As observed in the general population, the antibody response to COVID-19 vaccination was associated with protection of kidney transplant recipients against BTI with VOC (20). As already published in the general population, the strongest association with protection against BTI in SOT was observed with Wuhan neutralizing antibody titer (18, 20). In addition to SARS-CoV-2 neutralization, antibodies mediate viral control via Fc-dependent effector functions, including ADCP. We observed high correlations between the titers of binding, neutralizing and ADCP-promoting antibodies against SARS-CoV-2 RBD and S1 subunit, indicating a strong coordination between the diverse effector components of the antibody response. S1-specific ADCP-promoting IgG were higher in patients who remained free of BTI following booster vaccination, supporting the notion that they may also contribute to vaccine-induced protection. In contrast, S2-specific binding and ADCP-promoting IgG were similar in patients who developed or did not develop BTI. This observation suggests a dominant role of S1-specific antibodies in mediating protection against BTI in this population.

The S2-specific IFN- $\gamma$  response to booster vaccination was the second most important predictor of BTI. As no significant association was observed with S1-specific IFN- $\gamma$  responses, our data suggest a differential role of SARS-CoV-2 subunits in mediating protection following mRNA vaccination. As the S2 subunit is more conserved than the S1 subunit across SARS-CoV-2 VOC, it may be an important target for cell-mediated immunity against the delta and omicron variants to which our study population was exposed. To our knowledge, this is the first study indicating a role for cellular immune response to vaccination in protection against COVID-19. As suggested by Kent et al, a role for T cell immunity may be difficult to reveal in healthy adults who have optimal antibody responses to vaccination that may dominate protective immunity against COVID-19 (22). The suboptimal humoral immune response to vaccination

1 observed in SOT recipients may increase the importance of cellular immune responses in this  
2 population. Supporting this notion, a role for vaccine-induced T cell immunity in the context of  
3 low humoral immunity was shown in non-human primate studies of COVID-19 (26).

4

5 This study has several limitations. First, its sample size is relatively low because it was a single  
6 centre study. This limitation was decreased by the high incidence of symptomatic BTI during a  
7 period when delta and omicron VOC were dominant, allowing us to detect statistically  
8 significant associations with immunological parameters. A larger sample size may have  
9 allowed us to detect significant associations with demographic and clinical parameters. Further  
10 studies of correlates of protection in SOT recipients are needed to validate our observations.  
11 Second, the study did not include systematic screening of SARS-CoV-2 by PCR and therefore  
12 did not allow us to diagnose asymptomatic SARS-CoV-2 BTI. Such systematic screening was  
13 considered too challenging by the patients and by the study team. Instead, priority was placed  
14 on diagnosing symptomatic BTI, which we consider to be diagnosed with high sensitivity.  
15 Third, the study does not provide information regarding immunity against severe COVID-19,  
16 as most patients experiencing a BTI received therapeutic monoclonal antibodies and  
17 consequently presented mostly mild symptoms. Finally, while the very strong dominance of  
18 delta and omicron VOC in the Belgian population during the study period indicates that these  
19 were likely the cause of BTI in our study population, sequencing of SARS-CoV-2 was not  
20 performed systematically following diagnosis of BTI. Differences in correlates of protection  
21 against delta and omicron variants have been suggested and may have influenced our results  
22 (27).

23 In conclusion, this study shows that humoral and cellular immune responses induced by booster  
24 vaccination correlate with protection against SARS-CoV-2 BTI in kidney transplant recipients.  
25 These data emphasize the importance of reaching and maintaining a high level of immunity

1 through vaccination in this vulnerable population and suggest that vaccines inducing potent  
2 cellular immune responses, such as mRNA vaccines, may be particularly useful in populations  
3 with suboptimal humoral immune responses to vaccination.

4

## 5 **MATERIALS AND METHODS:**

### 6 *Study design and population*

7 This single centre prospective phase IV investigator-initiated study of the immunogenicity of  
8 the BNT162b2 vaccine (Pfizer-BioNTech) in kidney transplant recipients was approved by the  
9 ethics committee of the Erasme Hospital (P2020/284 and A2021/131) and by the Belgian  
10 Federal Agency for Medicines and Health Products (FAMHP, EudraCT 2021-000-412-28).  
11 Kidney transplant recipients aged at least 18 years were recruited in the Department of  
12 Nephrology, Dialysis and Transplantation of the Erasme Hospital, Belgium. They were  
13 informed and gave informed consent before administration of the first dose of BNT162b2  
14 vaccine. Patients transplanted with multiple organs were excluded from the study. Patients  
15 infected with SARS-CoV-2 before BNT162b2 vaccination were not included in this report.  
16 Previous SARS-CoV-2 infection was defined as a history of a positive PCR on nasopharyngeal  
17 swab before study recruitment and/or a positive serology (Wantai SARS-CoV-2 IgG Elisa, see  
18 Supplementary methods) at recruitment, before administration of the first dose of BNT162b2  
19 vaccine. Patients were seen by a study clinician at enrolment before the first dose, one month  
20 after the second dose and the day of the third dose of vaccine. Demographic and clinical data  
21 were recorded, including age, gender, body mass index, comorbidities (hypertension, diabetes,  
22 cardiovascular disease, chronic kidney insufficiency defined with eGFR < 30mL/min in CKD-  
23 EPI and evolutive or treated cancer), characteristics of transplantation history (duration, rank,  
24 graft function, induction treatment and immunosuppressive drugs), and absolute lymphocyte  
25 count.

1 All patients received the BNT162b2 vaccine at day 0 and day 21, according to the Belgian  
2 national vaccination program. The first vaccine dose was administered between March 2<sup>nd</sup> and  
3 March 18<sup>th</sup>, 2021, and the second dose between March 23<sup>rd</sup> and April 8<sup>th</sup>, 2021. The third dose  
4 of BNT162b2 vaccine was administered between August 17<sup>th</sup> and 20<sup>th</sup>, 2021, following an  
5 amendment of the study protocol approved by the Belgian FAMHP. BNT162b2 is a lipid  
6 nanoparticle–formulated, nucleoside-modified mRNA vaccine encoding a prefusion stabilized,  
7 membrane-anchored SARS-CoV-2 full-length spike protein (28). The 30µg/0.3 mL dose was  
8 administered by intra-muscular injection into the upper arm. Vaccines were administered by a  
9 trained study nurse at Erasme Hospital. Participants were observed for a minimum of 15  
10 minutes after vaccination. No serious adverse events were observed.

11

#### 12 *Breakthrough infection*

13 Following recruitment, symptomatic SARS-CoV-2 breakthrough infections (BTI), defined as  
14 the occurrence of fever, chills, cough, dyspnoea, rhinitis, anosmia, dysgeusia, abdominal pain  
15 or diarrhoea, associated with a positive SARS-CoV-2 PCR on nasopharyngeal swab, were  
16 recorded. Patients were informed of symptoms compatible with COVID-19 and were  
17 encouraged to be tested by PCR of a nasopharyngeal swab in case of such symptoms. Patients  
18 were regularly contacted by phone and/or by email to limit unreported BTI. The following data  
19 were recorded when a BTI was diagnosed: symptoms, date of symptom onset, oxygen  
20 requirement, organ failure and treatment, including curative monoclonal antibodies. The date  
21 of BTI was defined as the date of symptom onset. Only the first symptomatic BTI was included  
22 in the data analysis.

23

#### 24 *Immune response to BNT162b2 vaccination*

1 Humoral and cellular immune responses to BNT162b2 vaccination were measured one month  
2 after the second vaccine dose (D2D28) and one month after the third vaccine dose (D3D28).  
3 Pre-vaccination immune responses to SARS-CoV-2 were analyzed as baseline. Humoral  
4 immune responses measured included SARS-CoV-2 receptor binding domain (RBD)-specific  
5 binding IgG and avidity, SARS-CoV-2 Wuhan, B.1.617.2 Delta variant (83DJ-1), BA.1  
6 Omicron variant and BA.2 Omicron variant neutralizing antibodies, and SARS-CoV-2 S1 and  
7 S2 domain binding and phagocytosis inducing IgG. Cellular immune responses measured  
8 included S1 and S2 domain-specific IFN- $\gamma$ -producing cells. For detailed laboratory methods,  
9 see Supplementary Material.

10

#### 11 *Statistical analyzes*

12 Occurrence of SARS-CoV-2 BTI during the study period (from March 2<sup>nd</sup>-18<sup>th</sup>, 2021, to  
13 February 1<sup>st</sup>, 2022) was plotted as a Kaplan-Meier survival curve. The incidence of SARS-  
14 CoV-2 infection diagnosed in Belgium during the study period and the proportion of infections  
15 with variants of concern (VOC) circulating in Belgium were included in the graph to provide  
16 the epidemiological context of the study (29). Incidence rate (person-day rate) of BTI was  
17 defined as the ratio of breakthrough infections (BTI) divided by the time each patient was  
18 observed, totalled for all the patients. It was calculated for two different periods: (1) from the  
19 first day of vaccination to D3D28, and (2) from D3D28 to February 1<sup>st</sup>, 2022, when the fourth  
20 dose of COVID-19 vaccine was administered. Descriptive data were evaluated with geometric  
21 means (95% CI) for continuous variables, and n (% , 95% CI) for binary values. Descriptive  
22 data were compared by *t*-test or Wilcoxon-Mann-Whitney rank test for parametric and non-  
23 parametric values, respectively, according to D'Agostino normality test. A Wilcoxon signed  
24 rank test was used to test paired sampled, when comparing two time points. The proportion of  
25 participants with antibody levels higher than the lower limit of detection (LLOD) at D2D28 or



1 D3D28 were calculated for SARS-CoV-2 RBD binding IgG (LLOD: 5.4 IU/mL according to  
2 WHO standard) and neutralizing antibodies (LLOD: 77 IU/mL according to WHO standard).  
3 For RBD binding IgG and neutralizing antibodies, antibody concentrations below the limit of  
4 detection were assigned a value equal to half of the LLOD before transformation. RBD IgG  
5 avidity was measured for samples with detectable binding RBD IgG only. For IFN- $\gamma$  ELISpot,  
6 data equal to 0 or less than 0 after subtraction of background were assigned a value of 1 before  
7 transformation. Values higher than 300 spots forming cells/250,000 PBMC were censured at  
8  $1.200/10^6$  PBMC. The proportion of participants with cellular responses higher than an  
9 arbitrary cut-off of 50 SFC/ $10^6$  PBMC in IFN- $\gamma$  ELISpot were calculated at D2D28 or D3D28.  
10 Association between immune variables and demographic and clinical variables were explored  
11 by linear regressions. Univariate logistic regression was used to explore the factors associated  
12 with the occurrence of BTI for the period between D3D28 and February 1<sup>st</sup>, 2022. Variables  
13 with a p-value < 0.1 in univariate analyzes were included in a variance inflation factor (VIF)  
14 analysis. To avoid multi-collinearity, only variables with VIF<10 were included in multivariate  
15 analysis. A multivariate logistic regression model was built to analyze risk factors of BTI,  
16 adjusting for age, kidney graft function and mycophenolate mofetil use, considered as important  
17 variables influencing immune responses to SARS-CoV-2 vaccination, based on our linear  
18 regression data and on published data (30, 31). Missing data were excluded from the final  
19 analysis. The final model was selected based on backward selection of variables. All statistical  
20 analyzes were done using R version 4.2.0 (32).

21

1	<b>Supplementary Materials:</b>	
2		
3	Supplementary methods .....	2
4	• Clinical sample processing and storage .....	2
5	• Enzyme-linked immunosorbent assay .....	2
6	• SARS-CoV-2 Neutralizing Antibodies .....	3
7	• RBD IgG Avidity .....	3
8	• Enzyme-linked immunosorbent spot Spike-specific cellular responses .....	4
9	• Luminex profiling .....	5
10	• Phagocytosis Assays .....	6
11	Supplementary illustrations .....	7
12	• table S1. Demographic and clinical characteristics of naive kidney recipients at	
13	baseline .....	7
14	• table S2. Characteristics of symptomatic SARS-CoV-2 BTI. ....	9
15	• table S3. Humoral and cellular immune responses at D2D28 and D3D28.....	10
16	• table S4. Univariate analysis assessing the relation between breakthrough	
17	infections and clinical or immunological variables .....	12
18	• table S5. Linear regression assessing the association between immune parameters	
19	and demographical or clinical variables.....	14
20	• table S6. Binding and neutralizing antibody titers by variant of concern after three	
21	vaccine doses (D3D28). ....	15

## 1 **References and Notes:**

- 2 1. L. R. Requião-Moura, T. V. de Sandes-Freitas, L. A. Viana, M. P. Cristelli, L. G. M. de  
3 Andrade, V. D. Garcia, C. M. C. de Oliveira, R. de M. Esmeraldo, M. Abbud Filho, A. Pacheco-  
4 Silva, K. C. Sousa, A. R. Vicari, K. M. A. H. Costa, D. R. Simão, M. V. de Sousa, J. B. Campos,  
5 R. A. M. de B. Almeida, L. M. Deboni, M. M. Neto, J. A. Zanocco, H. Tedesco-Silva, J.  
6 Medina-Pestana, COVID-19-KT Brazil, High mortality among kidney transplant recipients  
7 diagnosed with coronavirus disease 2019: Results from the Brazilian multicenter cohort study.  
8 *PLoS One* **16**, e0254822 (2021).
- 9 2. F. Villanego, A. Mazuecos, I. M. Pérez-Flores, F. Moreso, A. Andrés, C. Jiménez-Martín,  
10 M. Molina, C. Canal, L. A. Sánchez-Cámara, S. Zárraga, M. del C. Ruiz-Fuentes, M. J. Aladrén,  
11 E. Melilli, V. López, E. Sánchez-Álvarez, M. Crespo, J. Pascual, for the S. S. of N. C.-19  
12 Group, Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic  
13 waves: Analysis of the Spanish Registry. *American Journal of Transplantation* **21**, 2573–2582  
14 (2021).
- 15 3. L. B. Hilbrands, R. Duivenvoorden, P. Vart, C. F. M. Franssen, M. H. Hemmelder, K. J.  
16 Jager, L. M. Kieneker, M. Noordzij, M. J. Pena, H. de Vries, D. Arroyo, A. Covic, M. Crespo,  
17 E. Goffin, M. Islam, Z. A. Massy, N. Montero, J. P. Oliveira, A. Roca Muñoz, J. E. Sanchez,  
18 S. Sridharan, R. Winzeler, R. T. Gansevoort, ERACODA Collaborators, COVID-19-related  
19 mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration.  
20 *Nephrol Dial Transplant* **35**, 1973–1983 (2020).
- 21 4. K. J. Jager, A. Kramer, N. C. Chesnaye, C. Couchoud, J. E. Sánchez-Álvarez, L. Garneata,  
22 F. Collart, M. H. Hemmelder, P. Ambühl, J. Kerschbaum, C. Legeai, M. D. Del Pino Y Pino,  
23 G. Mircescu, L. Mazzoleni, T. Hoekstra, R. Winzeler, G. Mayer, V. S. Stel, C. Wanner, C.  
24 Zoccali, Z. A. Massy, Results from the ERA-EDTA Registry indicate a high mortality due to

- 1 COVID-19 in dialysis patients and kidney transplant recipients across Europe. *Kidney Int* **98**,  
2 1540–1548 (2020).
- 3 5. E. J. Williamson, A. J. Walker, K. Bhaskaran, S. Bacon, C. Bates, C. E. Morton, H. J. Curtis,  
4 A. Mehrkar, D. Evans, P. Inglesby, J. Cockburn, H. I. McDonald, B. MacKenna, L. Tomlinson,  
5 I. J. Douglas, C. T. Rentsch, R. Mathur, A. Y. S. Wong, R. Grieve, D. Harrison, H. Forbes, A.  
6 Schultze, R. Croker, J. Parry, F. Hester, S. Harper, R. Perera, S. J. W. Evans, L. Smeeth, B.  
7 Goldacre, Factors associated with COVID-19-related death using OpenSAFELY. *Nature* **584**,  
8 430–436 (2020).
- 9 6. S. Udomkarnjananun, S. J. Kerr, N. Townamchai, P. Susantitaphong, W. Tulvatana, K.  
10 Praditpornsilpa, S. Eiam-Ong, Y. Avihingsanon, Mortality risk factors of COVID-19 infection  
11 in kidney transplantation recipients: a systematic review and meta-analysis of cohorts and  
12 clinical registries. *Sci Rep* **11**, 20073 (2021).
- 13 7. B. J. Boyarsky, W. A. Werbel, R. K. Avery, A. A. R. Tobian, A. B. Massie, D. L. Segev, J.  
14 M. Garonzik-Wang, Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in  
15 Solid Organ Transplant Recipients. *JAMA* **325**, 2204 (2021).
- 16 8. S. Caillard, N. Chavarot, D. Bertrand, N. Kamar, O. Thaunat, V. Moal, C. Masset, M. Hazzan,  
17 P. Gatault, A. Sicard, J. M. Chemouny, J. P. Rerolle, C. Colosio, H. Francois, J. Bamoulid, N.  
18 Bouvier, A. Duvéau, D. Anglicheau, G. Blancho, Occurrence of severe COVID-19 in  
19 vaccinated transplant patients. *Kidney International* **0** (2021), doi:10.1016/j.kint.2021.05.011.
- 20 9. C. X. Qin, L. W. Moore, S. Anjan, R. Rahamimov, C. D. Sifri, N. M. Ali, M. K. Morales, D.  
21 S. Tsapepas, N. Basic-Jukic, R. A. Miller, D. van Duin, R. N. Santella, H. M. Wadei, P. D.  
22 Shah, N. Gage, M. Malinis, S. Aslam, E. Todesco, W. A. Werbel, R. K. Avery, D. L. Segev,

- 1 Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. *Transplantation*
- 2 **105**, e265 (2021).
  
- 3 10. Z. A. Yetmar, E. Bhaimia, D. M. Bierle, R. Ganesh, R. R. Razonable, Breakthrough
- 4 COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of
- 5 symptomatic cases and monoclonal antibody therapy. *Transplant Infectious Disease* **n/a**,
- 6 doi:10.1111/tid.13779.
  
- 7 11. S. Anjan, Y. Natori, A. A. Fernandez Betances, M. S. Agritelley, A. Mattiazzi, L.
- 8 Arosemena, D. M. Andrews, J. Simkins, G. Guerra, L. M. Abbo, Breakthrough COVID-19
- 9 Infections After mRNA Vaccination in Solid Organ Transplant Recipients in Miami, Florida.
- 10 *Transplantation* **105**, e139–e141 (2021).
  
- 11 12. J. Sun, Q. Zheng, V. Madhira, A. L. Olex, A. J. Anzalone, A. Vinson, J. A. Singh, E. French,
- 12 A. G. Abraham, J. Mathew, N. Safdar, G. Agarwal, K. C. Fitzgerald, N. Singh, U. Topaloglu,
- 13 C. G. Chute, R. B. Mannon, G. D. Kirk, R. C. Patel, National COVID Cohort Collaborative
- 14 (N3C) Consortium, Association Between Immune Dysfunction and COVID-19 Breakthrough
- 15 Infection After SARS-CoV-2 Vaccination in the US. *JAMA Intern Med* **182**, 153–162 (2022).
  
- 16 13. N. Kamar, F. Abravanel, O. Marion, C. Couat, J. Izopet, A. Del Bello, Three Doses of an
- 17 mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. *New England Journal of*
- 18 *Medicine* **0**, null (2021).
  
- 19 14. I. Benotmane, G. Gautier, P. Perrin, J. Olagne, N. Cognard, S. Fafi-Kremer, S. Caillard,
- 20 Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney
- 21 Transplant Recipients With Minimal Serologic Response to 2 Doses. *JAMA* **326**, 1063–1065
- 22 (2021).

- 1 15. A. H. Karaba, X. Zhu, T. Liang, K. H. Wang, A. G. Rittenhouse, O. Akinde, Y. Eby, J. E.  
2 Ruff, J. N. Blankson, A. T. Abedon, J. L. Alejo, A. L. Cox, J. R. Bailey, E. A. Thompson, S. L.  
3 Klein, D. S. Warren, J. M. Garonzik-Wang, B. J. Boyarsky, I. Sitaras, A. Pekosz, D. L. Segev,  
4 A. A. R. Tobian, W. A. Werbel, A third dose of SARS-CoV-2 vaccine increases neutralizing  
5 antibodies against variants of concern in solid organ transplant recipients. *Am J Transplant* **22**,  
6 1253–1260 (2022).
- 7 16. T. W. Hoffman, B. Meek, G. T. Rijkers, D. A. van Kessel, Serologic response to a third  
8 dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients. *Transpl Immunol*  
9 **72**, 101599 (2022).
- 10 17. S. Feng, D. J. Phillips, T. White, H. Sayal, P. K. Aley, S. Bibi, C. Dold, M. Fuskova, S. C.  
11 Gilbert, I. Hirsch, H. E. Humphries, B. Jepson, E. J. Kelly, E. Plested, K. Shoemaker, K. M.  
12 Thomas, J. Vekemans, T. L. Villafana, T. Lambe, A. J. Pollard, M. Voysey, Correlates of  
13 protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med* **27**, 2032–  
14 2040 (2021).
- 15 18. D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K.  
16 Subbarao, S. J. Kent, J. A. Triccas, M. P. Davenport, Neutralizing antibody levels are highly  
17 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205–  
18 1211 (2021).
- 19 19. M. Bergwerk, T. Gonen, Y. Lustig, S. Amit, M. Lipsitch, C. Cohen, M. Mandelboim, E.  
20 Gal Levin, C. Rubin, V. Indenbaum, I. Tal, M. Zavitan, N. Zuckerman, A. Bar-Chaim, Y.  
21 Kreiss, G. Regev-Yochay, Covid-19 Breakthrough Infections in Vaccinated Health Care  
22 Workers. *New England Journal of Medicine* **0**, null (2021).

- 1 20. D. Cromer, M. Steain, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, S. J. Kent, J.  
2 A. Triccas, D. S. Khoury, M. P. Davenport, Neutralising antibody titres as predictors of  
3 protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *Lancet*  
4 *Microbe* **3**, e52–e61 (2022).
- 5 21. Y. Lustig, T. Gonen, L. Meltzer, M. Gilboa, V. Indenbaum, C. Cohen, S. Amit, H. Jaber,  
6 R. Doolman, K. Asraf, C. Rubin, R. Fluss, E. Mendelson, L. Freedman, G. Regev-Yochay, Y.  
7 Kreiss, Superior immunogenicity and effectiveness of the third compared to the second  
8 BNT162b2 vaccine dose. *Nat Immunol* **23**, 940–946 (2022).
- 9 22. S. J. Kent, D. S. Khoury, A. Reynaldi, J. A. Juno, A. K. Wheatley, E. Stadler, E. John  
10 Wherry, J. Triccas, S. C. Sasson, D. Cromer, M. P. Davenport, Disentangling the relative  
11 importance of T cell responses in COVID-19: leading actors or supporting cast? *Nat Rev*  
12 *Immunol* **22**, 387–397 (2022).
- 13 23. J.-M. Yamal, S. Appana, M. Wang, L. Leon-Novelo, E. Bakota, Y. Ye, S. Sharma, A. C.  
14 Morrison, D. Marko, S. H. Linder, A. Rector, K. K. Jetelina, E. Boerwinkle, M. de Oliveira  
15 Otto, Trends and Correlates of Breakthrough Infections With SARS-CoV-2. *Frontiers in Public*  
16 *Health* **10** (2022).
- 17 24. D. L. MD, E. Barkley, J. Kibitel, N. C. PharmD, J. McNitt, Which Comorbidities Increase  
18 the Risk of a COVID-19 Breakthrough Infection? *Epic Research* (available at  
19 [https://epicresearch.org/articles/which-comorbidities-increase-the-risk-of-a-covid-19-](https://epicresearch.org/articles/which-comorbidities-increase-the-risk-of-a-covid-19-breakthrough-infection)  
20 [breakthrough-infection](https://epicresearch.org/articles/which-comorbidities-increase-the-risk-of-a-covid-19-breakthrough-infection)).
- 21 25. P. S. Heeger, C. P. Larsen, D. L. Segev, Implications of defective immune responses in  
22 SARS-CoV-2–vaccinated organ transplant recipients. *Science Immunology* **6**, eabj6513 (2021).

- 1 26. K. McMahan, J. Yu, N. B. Mercado, C. Loos, L. H. Tostanoski, A. Chandrashekar, J. Liu,  
2 L. Peter, C. Atyeo, A. Zhu, E. A. Bondzie, G. Dagotto, M. S. Gebre, C. Jacob-Dolan, Z. Li, F.  
3 Nampanya, S. Patel, L. Pessaint, A. Van Ry, K. Blade, J. Yalley-Ogunro, M. Cabus, R. Brown,  
4 A. Cook, E. Teow, H. Andersen, M. G. Lewis, D. A. Lauffenburger, G. Alter, D. H. Barouch,  
5 Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature* **590**, 630–634  
6 (2021).
- 7 27. N. B. Stærke, J. Reekie, H. Nielsen, T. Benfield, L. Wiese, L. S. Knudsen, M. B. Iversen,  
8 K. Iversen, K. Fogh, J. Bodilsen, M. R. Juhl, S. O. Lindvig, A. Øvrehus, L. W. Madsen, V.  
9 Klastrup, S. D. Andersen, A. K. Juhl, S. R. Andreasen, S. R. Ostrowski, C. Erikstrup, T. K.  
10 Fischer, M. Tolstrup, L. Østergaard, I. S. Johansen, J. Lundgren, O. S. Søgaaard, Levels of  
11 SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant  
12 breakthrough infections. *Nat Commun* **13**, 4466 (2022).
- 13 28. F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez, G.  
14 Pérez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S. Roychoudhury, K. Koury,  
15 P. Li, W. V. Kalina, D. Cooper, R. W. Frenck, L. L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer,  
16 S. Ünal, D. B. Tresnan, S. Mather, P. R. Dormitzer, U. Şahin, K. U. Jansen, W. C. Gruber,  
17 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* ,  
18 NEJMoa2034577 (2020).
- 19 29. Belgium COVID-19 Dashboard - Sciensano *Google Data Studio* (available at  
20 [http://datastudio.google.com/reporting/c14a5cfc-cab7-4812-848c-](http://datastudio.google.com/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/urrUC?feature=opengraph)  
21 [0369173148ab/page/urrUC?feature=opengraph](http://datastudio.google.com/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/urrUC?feature=opengraph)).
- 22 30. T. Hamaya, S. Hatakeyama, T. Yoneyama, Y. Tobisawa, H. Kodama, T. Fujita, R.  
23 Murakami, N. Fujita, T. Okamoto, H. Yamamoto, T. Yoneyama, Y. Hashimoto, H. Saitoh, S.  
24 Narumi, H. Tomita, C. Ohyama, Seroprevalence of SARS-CoV-2 spike IgG antibodies after



1 the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients. *Sci Rep* **12**,  
2 5876 (2022).

3 31. K. Manothummetha, N. Chuleerarux, A. Sanguankeo, O. S. Kates, N. Hirankarn, A.  
4 Thongkam, M. V. Dioverti-Prono, P. Torvorapanit, N. Langsiri, N. Worasilchai, C. Moonla, R.  
5 Plongla, W. M. Garneau, A. Chindamporn, P. Nissaisorakarn, T. Thanियavarn, S. Nematollahi,  
6 N. Permpalung, Immunogenicity and Risk Factors Associated With Poor Humoral Immune  
7 Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic  
8 Review and Meta-Analysis. *JAMA Network Open* **5**, e226822 (2022).

9 32. R: The R Project for Statistical Computing (available at <https://www.r-project.org/>).

10

1 **Acknowledgments:**

2 **General:**

3 We thank Sorya Fagnoul and Emilie Navaux for the help in the recruitment and follow-up of  
4 patients. Maria Spanu and Anne Gillardin for the sampling and the follow-up of patients. Inès  
5 Vu Duc, Florian Ballieu, Vianney Nana Tchouta, Marie-Annick Ottou Eyenga, Sara Cuman,  
6 Robin Van Naemen and Caroline Rodeghiero for technical assistance. We thank the Robotein®  
7 platform of the BE Instruct-ERIC Centre for providing access to the Octet HTX and the  
8 Microlab STAR liquid handling workstation. Finally, we thank all patients for their generous  
9 participation in the study.

10

11 **Funding:**

12 This study was co-funded by the Belgian Federal Government through Sciensano and by the  
13 Fonds de la Recherche Scientifique, F.R.S.-FNRS, Belgium.

14 D.K. received a PhD studentship from the F.R.S- FNRS, Belgium.

15 N.G. received a PhD studentship from the Fonds Erasme, Belgium.

16 A.M. is Research Director of the F.R.S.-FNRS, Belgium.

17

18 **Author Contributions:**

19 DK, NG, ALM and AM conceptualized the study. DK and PP wrote the clinical study protocol.

20 DK obtained permission from the ethics committee and AFMPS. MEG, ALM and AM secured  
21 the funding of the study. DK, NG and AL conducted the clinical study. ALM overviewed the  
22 clinical study. DK, NG, VO, DG, MV, AW, JM and LH conducted the laboratory analyzes.

23 AM, PP, ID, MEA, AMat and KKA overviewed the laboratory analyzes. DK, NG, SD, DG and  
24 LH analyzed the data. DK, NG, SD, MEA and AM interpreted the data. DK and AM drafted  
25 the manuscript. All co-authors reviewed and approved the manuscript.

1

2 **Competing interests:**

3 The authors declare no conflicts of interest.


4

5 **Data and materials availability:**

6 The datasets used and analyzed during the current study are available from the corresponding  
7 author on reasonable request, following materials transfer agreements.

1 **Figures:**


2




3

4 **Fig. 1. Study flow chart.**


1




1  
2 **Fig. 2. Occurrence of symptomatic breakthrough infection in relation to incidence of**  
3 **COVID-19 in the Belgian population.** The black line represents the proportion of kidney  
4 transplant recipients who remained free of SARS-CoV-2 BTI during the study period. Dotted  
5 lines are 95% confidence intervals. Day 0 is the date of the first vaccine dose for each patient.  
6 Patients were followed-up until the first day of administration of the 4<sup>th</sup> vaccine dose (February  
7 1<sup>st</sup>, 2022). Each cross represents a patient lost to follow-up. Numbers of patients with BTI, lost  
8 to follow-up and at risk of BTI are indicated in the lower part of the graph (black numbers:  
9 before the second vaccine dose; grey: between the second and third dose of vaccine; green: after  
10 the third vaccine dose). The grey line represents daily confirmed COVID-19 cases per million  
11 people 7 days rolling average in Belgium. Day 0 for the grey line is the median date of first  
12 vaccination of the study population (March 10<sup>th</sup>, 2021). Proportions of infections with VOC are  
13 presented in the upper part of the figure (alpha in green, delta in orange, omicron BA.1 in grey  
14 and omicron BA.2 in pink, and others in white).



1  
2 **Fig. 3. Immune response to second and third COVID-19 mRNA vaccinations in kidney**  
3 **transplant recipients.** Immune responses, including SARS-CoV-2 receptor binding domain  
4 (RBD)-specific binding IgG titer (RBD IgG) and avidity (RBD IgG avidity), SARS-CoV-2  
5 Wuhan neutralizing antibody titer (Wuhan NT<sub>50</sub>) and S1 (S1 IFN- $\gamma$ ) and S2 (S2 IFN- $\gamma$ ) domain-  
6 specific IFN- $\gamma$ -producing cells, were measured one month after the 2<sup>nd</sup> dose (D2D28) and one  
7 month after the 3<sup>rd</sup> dose (D3D28) of vaccine among kidney transplant recipients naive of  
8 symptomatic BTI at D3D28 (n=53). Each data point represents a sample. Samples were  
9 available for 51 patients at D2D28 and 53 patients at D3D28. The lower limit of detection  
10 (LLOD) is 5.4 IU/mL for RBD binding IgG and 77 IU/mL for Wuhan NT<sub>50</sub>. Twenty-one  
11 patients had detectable RBD binding IgG at D2D28 and 27 at D3D28. One patient had  
12 detectable neutralizing antibodies at D2D28 and 24 at D3D28. RBD IgG avidity was only  
13 measured for samples with RBD binding IgG levels > 5.4 IU/mL. Statistical comparisons were  
14 made using Wilcoxon signed rank test. RBD: receptor binding domain. Wuhan NT<sub>50</sub>: 50%  
15 neutralizing antibody titer against Wuhan strain. S1 or S2 IFN- $\gamma$ : S1 or S2 specific PMBC  
16 responses. \*\* p<0.01; and \*\*\*\* p<0.0001.



1  
2 **Fig. 4. Univariate analysis of risk factors of symptomatic breakthrough infection in kidney**  
3 **transplant recipients.** Univariate logistic regression was used to assess the relationship  
4 between immunological, demographic and clinical parameters and the occurrence of  
5 symptomatic BTI. Obesity was defined as BMI > 30 kg/m<sup>2</sup>. Transplantation rank was divided  
6 into first transplantation and second or more transplantation. Immunological parameters and  
7 absolute lymphocyte counts were log<sub>10</sub> transformed before analysis. RBD: receptor binding  
8 domain. Wuhan NT<sub>50</sub>: 50% neutralizing antibody titer against Wuhan strain. S1 or S2 IFN- $\gamma$ :  
9 S1 or S2-specific PMBC responses. eGFR: estimated glomerular function rate. OKT3:  
10 muromumab; ATG: anti-thymoglobulin. Ly count: absolute lymphocyte count.



1

2 **Fig. 5. Immune response to booster COVID-19 vaccination in kidney transplant recipients**

3 **with and without symptomatic BTI.** Humoral and cellular immune responses were measured

4 28 days after a third dose of BNT162b2 COVID-19 vaccine in 53 kidney transplant recipients

5 who developed (red symbols) or did not develop (blue symbols) symptomatic SARS-CoV-2

6 BTI following vaccination. Black bars indicate geometric means. Variables were compared

7 with Wilcoxon-Mann-Whitney test. \*  $p < 0.05$ ; \*\*  $p < 0.01$ . (A) SARS-CoV-2 receptor binding

8 domain (RBD)-specific binding IgG titer (RBD IgG) and avidity (RBD IgG avidity), SARS-

9 CoV-2 Wuhan neutralizing antibody titer (Wuhan NT<sub>50</sub>). (B) S1-specific binding IgG (S1 IgG),



1 S2-specific binding IgG (S2 IgG), S1-specific binding IgG antibody –dependant cellular  
2 phagocytosis (S1 IgG ADCP) and S2-specific binding IgG antibody –dependant cellular  
3 phagocytosis (S1 IgG ADCP). **(C)** S1-specific cells producing IFN- $\gamma$  (S1 IFN- $\gamma$ ) and S2-  
4 specific cells producing IFN- $\gamma$  (S2 IFN- $\gamma$ ). **(D)** Pearson correlation matrix of immune response  
5 parameters. Correlation coefficients are color coded. Circle size indicates the absolute value of  
6 corresponding correlation coefficients. All correlations were statistically significant, except  
7 those marked by a cross instead of a circle.